Enhancing immunogenicity and cross-reactivity of HIV-1 antigens byin vivotargeting to dendritic cells-Reference-Cited by-同舟云学术

Enhancing immunogenicity and cross-reactivity of HIV-1 antigens byin vivotargeting to dendritic cells

Published:2012-10 Issue:10 Volume:7 Page:1591-1610
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

Cruz Luis J¹,Rueda Felix²,Tacken Paul³,Albericio Fernando⁴⁵,Torensma Ruurd³,Figdor Carl G³

Affiliation:

1. Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands; Endocrinology Research Lab and Molecular Imaging, Leiden University Medical Center, Building 1, C4-R67, Albinusdreef 2, 2333ZA Leiden, The Netherlands.

2. Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain

3. Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands; Endocrinology Research Lab and Molecular Imaging, Leiden University Medical Center, Building 1, C4-R67, Albinusdreef 2, 2333ZA Leiden, The Netherlands

4. Institute for Research in Biomedicine and CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Barcelona Science Park, Baldiri Reixac 10, 08028 Barcelona, Spain

5. School of Chemistry, University of KwaZulu-Natal, 4041 Durban, South Africa

Abstract

Current retroviral treatments have reduced AIDS to a chronic disease for most patients. However, given drug-related side effects, the emergence of drug-resistant strains and the persistence of viral replication, the development of alternative treatments is a pressing need. This review focuses on recent developments in HIV immunotherapy treatments, with particular emphasis on current vaccination strategies for optimizing the induction of an effective immune response by the recruitment of dendritic cells. In addition to cell-based therapies, targeted strategies aiming to deliver synthetic HIV peptides to dendritic cell-specific receptors in vivo will be discussed.

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm.12.131

Reference170 articles.

1. T Cell Dynamics in HIV-1 Infection

2. Uridine Metabolism in HIV-1-Infected Patients: Effect of Infection, of Antiretroviral Therapy and of HIV-1/ART-Associated Lipodystrophy Syndrome

3. Progress on new vaccine strategies against chronic viral infections

4. Current Prospects for the Development of a Therapeutic Vaccine for the Treatment of HIV Type 1 Infection

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy;Pharmaceutics;2021-10-13

2. Delivering safer immunotherapies for cancer;Advanced Drug Delivery Reviews;2017-05

3. Cell-Based Biologic Therapy for the Treatment of Medical Diseases;Therapeutic Delivery Solutions;2014-08-22

4. Increased Generation of HIV-1 gp120-Reactive CD8+ T Cells by a DNA Vaccine Construct Encoding the Chemokine CCL3;PLoS ONE;2014-08-14

5. CD4 T Cell Help Is Limiting and Selective during the Primary B Cell Response to Influenza Virus Infection;Journal of Virology;2013-10-23